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ABSTRACT 
Background. Multiple sclerosis (MS) is often considered to be a CD4, T cell-mediated disease. 
This is largely based on the capacity of CD4 T cells to induce relapsing experimental autoimmune 
encephalomyelitis (EAE) in rodents. However, CD4-depletion using a monoclonal antibody was 
considered unsuccessful and relapsing MS responds well to B cell depletion via CD20 B cell 
depleting antibodies. The influence of CD20 B cell depletion in relapsing EAE was assessed.  
Methods. Relapsing EAE was induced in Biozzi ABH mice. These were treated with CD20-specific 
(18B12) antibody and the influence on CD45RA-B220 B cell depletion and clinical course was 
analysed. 
Results. Relapsing EAE in Biozzi ABH failed to respond to the marked B cell depletion induced 
with a CD20-specific antibody. In contrast to CD20 and CD8-specific antibodies, CD4 T cell 
depletion inhibited EAE.  
Conclusion. Spinal cord antigen-induced disease in ABH mice is CD4 T cell-dependent. The lack 
of influence of CD20 B cell depletion in relapsing EAE, coupled with the relatively marginal and 
inconsistent results obtained in other mouse studies, suggests that rodents may have limited 
value in understanding the mechanism occurring following CD20 B cell depletion in humans. 
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HIGHLIGHTS 
● CD20+ B cell depletion did not inhibit relapsing EAE. 
● Even when therapeutic, the results following CD20+ depletion are marginal and 
inconsistent between studies in rodents. 
● Rodent EAE studies are unlikely to expose the true mechanism of CD20-depleting 
antibodies in MS 
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INTRODUCTION 
Multiple sclerosis is the major demyelinating disease of the adult central nervous system 
(Compston & Coles 2008). This is thought by many, to represent a T cell-mediated autoimmune 
disease, largely based on a significant amount of circumstantial evidence from MS and notably by 
the induction and response to therapy of experimental autoimmune encephalomyelitis in animals 
(Martin et al. 2016). However the perceived failure of T cell depletion with CD4 specific antibodies 
(van Oosten et al 1997) and the robust inhibitory effect of a number CD20-specific B cell depleting 
antibodies (Bar-Or or et al 2008; Hauser et al. 2008, Sorensen et al. 2014, Hauser et al. 2017) 
in relapsing MS, may perhaps question the central role of T cells as targets to control MS (Baker 
et al. 2017). 
 
CD20 is a surface marker expressed by B cells from the pre-B cell to the memory B cell 
phenotypes, which is lost during differentiation into plasma cells (Tedder & Engel 1994). Depletion 
of these cells from the peripheral B cell pool can inhibit active MS (Cross et al. 2006, Bar-Or et 
al. 2008).  Whilst it has been suggested that CD20-specific mAb act via depletion of a pathogenic 
T cell subset (Palanichamy et al. 2014, Holley et al 2014), studies in rodents and MS have 
supported the view that memory B cells act as a central antigen presenting cell to drive T cell 
autoimmunity (Agahozo et al. 2016, Baker et al. 2017). However, studies using CD20-depleting 
antibodies in EAE have been variable and may augment or inhibit monophasic chronic EAE in 
C57BL/6 mice (Matsushita et al. 2008, Weber et al. 2010, Monson et al. 2011).   It was 
hypothesized that therapeutic depletion of B cells would inhibit relapsing EAE, in Biozzi ABH mice 
(Al-Izki et al. 2012), however surprisingly marked CD20 B cell depletion failed to influence EAE, 
in contrast to that found in MS.  
 
MATERIALS & METHODS 
 
Animals. Female Biozzi ABH (6-8 weeks) mice were purchased from Harlan UK Ltd (Bicester, 
UK). These were maintained on a 12h:12h light:dark cycle and were housed and fed with RM1(E) 
chow and water ad libitum as described previously (Al-Izki et al. 2012). These were used 
according to the United Kingdom, Animals (Scientific procedures) Act 1986, incorporating review 
by the local Animal Welfare and Ethical Review Body and the United Kingdom Home Office. 
 
Antibodies. Mouse CD4-specific rat IgG2b (YTS191) mAb and mouse CD8-specific rat IgG2b 
(YTS169) mAb were produced as described previously (O’Neill et al. 1993) and protein G purified 
using HiTrapTM protein G columns (Pharmacia/GE Healthcare Life Sciences, Amersham, UK) or 
was purchased from BioXCell (West Lebanon, New Hampshire, USA). 250µg mAb was injected 
intraperitoneally to deplete CD4 and CD8 T cells for 2-3 weeks (O’Neill et al. 1993). Mouse CD20-
specific mouse IgG2a (18B12. IgG2a variant. Hamel et al. 2008) was supplied by Biogen 
(Cambridge, USA). 250μg mAb, which induced marked depletion of B cells between 1-21 days in 
BALB/c mice (Hamel et al. 2008), was injected intravenously/mouse on day 8 or day 28. Animals 
were randomized within cages to control or treatments. Irrelevant rat IgG2b, and mouse IgG2a 
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mAb do not influence the course of EAE in ABH mice (O’Neill et al. 1993, Al-Izki et al. 2012). 
 
Flow Cytometry. Spleens were removed and single cell suspensions generated using a 40 μm 
cell strainer. Red cells were lysed by addition of 1 ml lysis buffer (4.14 g 15 mM Ammonium 
chloride, 0.5 g 10 mM Potassium bicarbonate and 2.5 ml 20 mM EDTA solution in 500 ml distilled 
water) for a minimum of 1 minute at room temperature. The number of viable cells was 
determined by trypan blue exclusion method and then 1 x 106 splenocytes were incubated with 
1-5µg/ml fluorescent mouse specific antibodies.  Terminal cardiac or tail bleeds were collected in 
heparin-coated tubes (Vet Labs, Pullborough, UK). 50 μl of blood sample was stained with CD3 
(145-2C11), CD4 (RM4-5), CD8 (53-6.7) or CD45RA/B220 (RA3-6B2) specific mAb (Becton 
Dickinson, Oxford, UK) in 2% heat-inactivated foetal calf serum (Invitrogen, Paisley, UK) in 
phosphate buffered serum (Invitrogen, Paisley, UK). Cells were incubated for 30 minutes in the 
dark at room temperature. Red cells were lysed by addition of 1 ml of 1:10 dilution of FACS Lysis 
Buffer (Becton Dickinson, Oxford, UK). Cells were vortexed and incubated for minimum of 1 
minute at room temperature and until solution goes clear red. Cells were fixed by addition of 100 
μl Caltag Medium A fixative (Caltag, Buckingham, UK) and incubated for minimum 15 minutes in 
the dark at room temperature. Samples were analysed by flow cytometry (Becton Dickinson, 
Oxford, UK).  
 
Induction of experimental autoimmune encephalomyelitis. 6-8 week adult ABH mice were 
subcutaneously injected with 1mg mouse spinal cord homogenate (SCH) emulsified in Freunds 
adjuvant containing 60μg Mycobacterium tuberculosis H37Ra and M. butyricum(8:1) in the flank 
on day 0 an 7 as described previously (Al-Izki et al. 2012). Relapse was induced by injecting the 
mice subcutaneously by a further set of injections on day 29 (Al-Izki et al. 2012). Clinical disease 
was scored: Normal = 0; Fully flaccid tail = 1; Impaired righting reflex = 2; Hindlimb paresis = 
3; Complete hindlimb paralysis = 4 and Moribund/death = 5 (Al-Izki et al. 2012). Details of 
randomization, blinding and sample size calculations and other experimental details relevant to 
the ARRIVE guidelines have been reported previously (Al-Izki et al. 2012). Use of SCH as 
immunogen precludes ex vivo analysis as SCH-sensitized animals fail to give robust T cell 
responses to the dominant pathological myelin epitopes.  
 
Statistical analysis. Flow cytometry was analysed by Analysis of Variance with a Bonferroni post 
hoc test. Results represent the mean maximum ± SEM clinical score or day of onset ± SD were 
analysed using non-parametric statistics using Sigma plot V11 (Systat Inc, San Jose,USA) 
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RESULTS 
CD20-specific antibody depletes B cell in the blood and spleen. 
To confirm the B cell depleting capabilities of CD20-specific mAb, 250µg 18B12 mouse IgG2 
variant was injected into Biozzi ABH mice and blood and splenocytes sampled at baseline 7, 14 
and 21 days post-injection and the numbers of B cells assessed (Figure 1). As anticipated a single 
injection of 250µg mAb depleted the B cells for at least 3 weeks in both the blood (Figure 1A) and 
spleen (Figure 1B). 
 
Depletion of CD20-specific B cells fails to inhibit EAE 
  
Depletion with CD20-specific mAb after sensitization has been reported to inhibit EAE (Matsushita 
et al. 2008, Weber et al 2010). Therefore ABH mice were injected with CD20 B cell depleting mAb 
on day 8 prior to the onset of initial acute EAE (Figure 2A). There was no difference in incidence; 
day of onset, or the maximum severity of EAE (Figure 2A). In contrast similar treatment with 
CD4d depleting mAb inhibited the development of EAE, whereas CD8 T cell depletion failed to 
prevent the development of EAE, similar to CD20 B cell depletion (Figure 2B). This suggested that 
disease was not responsive to CD20 B cell depletion and was largely driven by the action of CD4 
T cells. Furthermore depletion of CD20 B cells did not influence the recovery from paralytic disease 
(Figure 2B). To assess whether CD20 could inhibit relapsing disease as a more therapeutically 
relevant situation and to determine whether depletion before the triggering stimulus could inhibit 
disease, CD20 B cell depletion was initiated before relapse was induced with a further injection of 
antigen in adjuvant (Figure 2C) and as was found in the initial phase of disease, CD20-depletion 
failed to inhibit the induced relapse. (Figure 2C). In addition a double dose of CD20 depletion on 
day 8 and again on day 28, failed to significantly inhibit the incidence, maximal severity or day of 
onset of an induced relapse (Table 1). Therefore despite marked CD20 B cell depletion there was 
no inhibition of relapsing EAE in ABH mice. 
 
DISCUSSION 
There have been numerous reports of the influence of genetic B cell depletion on EAE, which have 
supported some involvement of B cells (Agahozo et al. 2016). Likewise there have been a number 
of reports of CD20-depleting mAb influencing rodent EAE (Agahozo et al. 2016) and this effect 
can vary depending on the model, immunizing antigen and timing of onset (Figure 3. Matsushita 
et al. 2008). This can result in augmentation (Matsushita et al. 2008; Weber et al. 2010; Lehmann 
et al. 2011), inhibition (Matsushita et al. 2008; Weber et al. 2010; Lehmann-Horn et al. 2011; 
Monson et al. 2011, Anthony et al. 2014) or nothing (Matsushita et al. 2008) as seen here (Figure 
2). However, when the data is more critically appraised, it is evident that, even when a therapeutic 
effect was reported the influence was relatively marginal and is seen by a small delay and/or 
diminution in the severity of clinical disease, in what is a high optimised system (Figure 3A, B). 
This contrasts with the essential elimination of disease with agents such as fingolimod, CD4 or 
CD52 depleting mAb (Al-Izki et al. 2011; von Kutzleben et al. 2017). Perhaps the most compelling 
inhibition of disease occurred when rituximab was used to inhibit disease in human CD20 
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transgenic mice (Monson et al. 2011, Figure 3B). However, as that was associated with marked 
depletion of CD4 T cells (Monson et al. 2011. Figure 3B), that could easily account for any disease 
inhibition (von Kutzleben et al. 2017) as seen here. Although, T cell depletion does occur following 
CD20-depleting mAb administration in humans (Palanichamy et al. 2014) the level is modest and 
well below the level of CD4 T cell depletion that failed to influence MS using CD4 depleting 
antibodies  (van Oosten et al. 1997). This suggests either that there is a very specific subset of 
important T cells affected or that this activity may be irrelevant to the therapeutic action of CD20 
B cell depletion in MS (Baker et al. 2017).  
Whilst the influence of CD20 depletion on relapsing MS is comparable with the influence of CD52 
lymphocyte depletion (Cohen et al. 2012; Hauser et al. 2017), the level of disease inhibition in 
published studies in rodents is not particularly compelling (Figure 3). Importantly, there is no 
consistent effect of CD20-specific mAb responsiveness across the rodent models (Figure 3), such 
as the influence of timing of mAb administration (Matsushita et al. 2008, Weber et al. 2011, 
Monson et al. 2011). Whilst it has been reported that myelin peptide-induced disease may be 
relatively B cell-independent compared to myelin protein-induced disease (Weber et al. 2011), in 
this study we failed to find an influence on protein-induced disease and other studies with myelin-
peptide-induced disease has been influenced by CD20 depletion (Matsushita et al. 2008). This 
aspect is likewise not consistent and creates concern about the translatability of the results for 
rodents to humans (Baker & Amor 2014). As shown here, relapsing disease, at least in the ABH 
mouse is clearly not dependent on the action of CD20 B cells, which is consistent with the known 
CD4 T cell dependence (O’Neill et al. 1993; von Kutzleben et al. 2017). Although people may 
suggest the influence of CD20-B cell depletion is through the inhibition of antigen-presenting B 
cells function (Baker et al. 2017), if this were the case perhaps one may expect a more consistent 
effect in rodents, which is lacking (Figure 3).  
However, as MS is human specific (Compston & Coles 2008, Baker & Amor 2014), it may suggest 
that the central susceptibility issues are restricted to humans. Thus, whilst there is much focus 
on T cell autoimmunity, it seems that agents that target relapsing MS also have a major action 
on memory B cells (Baker et al. 2017). This subset is the primary target of persistent Epstein Barr 
Virus (EBV) infection, thus B cell depletion may be removing a human-specific aetiological risk 
factor (Baker et al. 2017). As specific-pathogen-free ABH mice develop EAE, without the apparent 
need for viral susceptibility factors, this perhaps accounts for the lack of marked influence of 
CD20-depletion in rodents. As such it is of interest that CD20-B cell depletion can be associated 
with disease inhibition in some marmosets (Kap et al. 2010). There has been suggested to act 
via targeting B cells infected with an EBV-analogue virus (t’Hart et al. 2013). Further studies to 
address these aspects are warranted. 
In conclusion, we have been unable to demonstrate any value in depleting CD20 B cells on the 
course of relapsing EAE. Further studies may define whether there is any influence in non-
relapsing progressive disease. However, there are clear biology differences between rodent and 
human B cells, as indicated by the distinct phenotypes and markers during B cell lineage 
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development (Anderson et al. 2007). Rodents also show differences in response to B cell therapy, 
this suggests that there may be limited translational value in rodent studies, for this aspect of 
MS. Furthermore, it may question the value and ability of further rodent studies to uncover a 
human-relevant mechanism concerning CD20-B cell depleting activity.  
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TABLE 1. CD20 B cell depletion does not inhibit relapsing EAE in ABH mice. 
Treatment Day No. Relapse Group Score EAE Score Onset Day 
Control 
CD20 mAb 
CD20 mAb 
CD20 mAb 
v, v 
8, v 
v, 28 
8, 28 
9/9 
7/7 
5/5 
5/6 
3.2 ± 0.2 
3.7 ± 0.1 
3.3 ± 0.2 
3.1 ± 0.5 
3.2 ± 0.2 
3.7 ± 0.1 
3.3 ± 0.2 
3.6 ± 0.2 
35.6 ± 1.6 
35.0 ± 0.6 
34.4 ± 0.5 
38.8 ± 5.9 
Biozzi ABH mice were injected with spinal cord homogenate on day 0 and 7 with spinal cord homogenate in 
Freunds adjuvant and repeated on day 29 to induce a relapse. (A) Animals were injected with vehicle (v) or 
250µg CD20 depleting mAb on day 8, 28 or day 8 and 28.  The results represent the mean maximal clinical score 
± SEM, the mean maximal clinical score of animals with relapse ± SEM (EAE score) and day of onset of relapse 
± SD. The was no statistically significant differences between the CD20 mAb groups and the control group 
(Mann Whitney U) 
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Figure 1. Depletion of B cells by CD20-specific mAb in Biozzi ABH mice. 
 
   
Following the injection of 250µg CD20-specific mAb i.v. (A) Peripheral blood lymphocytes and (B) 
splenocytes were stained to detect B220 positive B cells within gated lymphocytes. The results 
represent individual results (n= 3-7). *P<0.95, **P<0.01, *** P<0.001 compared to untreated 
animals. 
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Figure 2. CD20 B cell depletion does not inhibit clinical EAE 
 
 
Animals were injected with spinal cord homogenate on (A-C) day 0 and 7 with spinal cord homogenate in 
Freunds adjuvant and (C) repeated on day 29 to induce a relapse. (A) Animals were untreated (n = 10) or were 
injected with 250µg CD20 depleting mAb on day 8 (n = 10) or were (B) treated with vehicle (PBS. n = 18) with 
CD4 depleting (CD4d. n=16), CD8 depleting (CD8d n=8) of CD20 depleting (CD20d. n=10) mAb. (C) Animals 
were untreated (n=9) or were injecte with 250µg CD20 depleting mAb i.v. on day 28 (n = 9). The results 
represent (A, C) The mean daily clinical score ± SEM or (B) Kaplan Meier survival curve showing the onset of 
disease   
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Figure 3. Influence of CD20 B cell depletion in rodent encephalomyelitis 
 
 
 
(A) Wildtype C57BL/6 mice were immunized with MOG35-55 peptide were injected with mouse CD20 
mouse IgG2c B cell depleting mAb at various times before and after immunization. Reproduced 
with permission from American Association of Clinical Investigation. Matsushita et al. 2008. J. Clin 
Invest. doi:10.1172/JCI36030. (B) Human CD20 transgenic C57BL/6 mice were immunized with 
recombinant MOG protein and treated with human CD20 reactive chimeric human IgG1 antibody. 
Spleens were harvested and stained with CD19 or CD4 specific antibodies. Reproduced under the 
Creative Commons Attribution License. PLoSOne Monson et al. 2011 DoI 10.1371/ 
journal.pone.0017103. (C) Human CD20 transgenic C57BL/6 mice were immunized with 
recombinant MOG protein and treated with human CD20 reactive mouse IgG2a antibody at weekly 
intervals from day-21 or following onset. Reproduced with permission from John Wiley & Sons. 
Annal Neurol. Weber et al. 2010. doi: 10.1002/ana.22081. 
